title: Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary.
abstract: Preservation of ovarian function following chemotherapy for nonovarian cancers is a formidable challenge. For prepubescent girls, the only option to prevent chemotherapy damage to the ovary is ovarian tissue cryopreservation, an experimental procedure requiring invasive surgeries to harvest and reimplant tissue, which carries the risk of cancer reintroduction. Drugs that block the primary mechanism of chemotherapy insult, such as dexrazoxane (Dexra) in the context of anthracycline chemotherapy, provide a novel approach for ovarian protection and have the potential to overcome current limitations to oncofertility treatment. Dexra is a catalytic topoisomerase 2 inhibitor that protects the mouse ovary from acute doxorubicin (DXR) chemotherapy toxicity in vitro by preventing DXR-induced DNA damage and subsequent gammaH2AX activation. To translate acute DXR ovarian insult and Dexra protection from mouse to nonhuman primate, freshly obtained marmoset ovarian tissue was cultured in vitro and treated with vehicle or 20 μM Dexra 1 h prior to 50 nM DXR. Cultured ovarian tissue was harvested at 2, 4, or 24 h post-DXR treatment. Dexra prevented DXR-induced DNA double-strand breaks as quantified by the neutral comet assay. DXR treatment for 24 h increased gammaH2AX phosphorylation, specifically increasing the number of foci-positive granulosa cells in antral follicles, while Dexra pretreatment inhibited DXR-induced gammaH2AX phosphorylation foci formation. Additionally, Dexra pretreatment trended toward attenuating DXR-induced AKT1 phosphorylation and caspase-9 activation as assayed by Western blots of ovarian tissue lysates. The combined findings suggest Dexra prevents primary DXR-induced DNA damage, the subsequent cellular response to DNA damage, and may diminish early apoptotic signaling in marmoset ovarian tissue. This study provides initial translation of Dexra protection against acute ovarian DXR toxicity from mice to marmoset monkey tissue.
authors.affiliation: Department of Obstetrics and Gynecology, Divisions of Reproductive Endocrinology and Infertility and Reproductive Sciences, University of Wisconsin, Madison, Wisconsin sanasalih5@gmail.com.
authors.forename: Sana M
authors.initials: SM
authors.lastname: Salih
authors.affiliation: Department of Obstetrics and Gynecology, Divisions of Reproductive Endocrinology and Infertility and Reproductive Sciences, University of Wisconsin, Madison, Wisconsin.
authors.forename: Ashley K
authors.initials: AK
authors.lastname: Ringelstetter
authors.affiliation: Department of Obstetrics and Gynecology, Divisions of Reproductive Endocrinology and Infertility and Reproductive Sciences, University of Wisconsin, Madison, Wisconsin.
authors.forename: Mazin Z
authors.initials: MZ
authors.lastname: Elsarrag
authors.affiliation: Department of Obstetrics and Gynecology, Divisions of Reproductive Endocrinology and Infertility and Reproductive Sciences, University of Wisconsin, Madison, Wisconsin Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin.
authors.forename: David H
authors.initials: DH
authors.lastname: Abbott
authors.affiliation: Department of Obstetrics and Gynecology, Divisions of Reproductive Endocrinology and Infertility and Reproductive Sciences, University of Wisconsin, Madison, Wisconsin.
authors.forename: Elon C Roti
authors.initials: EC
authors.lastname: Roti
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002144:Callithrix; D053453:Caspase 9 / Q000378:metabolism; D004249:DNA Damage / Q000187:drug effects; D064730:Dexrazoxane / Q000494:pharmacology*; D004317:Doxorubicin / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D023421:Models, Animal; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D046509:Tissue Culture Techniques; D059005:Topoisomerase II Inhibitors / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D059005:Topoisomerase II Inhibitors; D064730:Dexrazoxane; D004317:Doxorubicin; D051057:Proto-Oncogene Proteins c-akt; D053453:Caspase 9
keywords: cancer survivor; dexrazoxane; doxorubicin; fertility; marmoset; ovary